Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Agenus Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Agenus wird ein Gewinn- und Umsatzwachstum von 10.7% bzw. 19.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 23.5% pro Jahr wachsen soll.

Wichtige Informationen

10.7%

Wachstumsrate der Gewinne

23.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	19.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Recent updates

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

FDA accepts Agenus' balstilimab BLA under "priority review" status

Jun 17

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

May 26

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:AGEN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	233	-208	21	N/A	5
12/31/2025	183	-223	-130	N/A	5
12/31/2024	206	-175	-58	N/A	5
3/31/2024	161	-240	-212	-204	N/A
12/31/2023	156	-246	-234	-224	N/A
9/30/2023	101	-271	-255	-231	N/A
6/30/2023	99	-263	-234	-198	N/A
3/31/2023	95	-240	-232	-182	N/A
12/31/2022	98	-220	-228	-175	N/A
9/30/2022	90	-215	-199	-151	N/A
6/30/2022	320	18	-42	13	N/A
3/31/2022	310	-19	-38	0	N/A
12/31/2021	296	-24	-24	10	N/A
9/30/2021	307	4	-28	-3	N/A
6/30/2021	69	-226	-170	-166	N/A
3/31/2021	85	-190	-150	-147	N/A
12/31/2020	88	-181	-143	-139	N/A
9/30/2020	91	-174	-139	-135	N/A
6/30/2020	97	-168	-135	-131	N/A
3/31/2020	85	-171	-134	-130	N/A
12/31/2019	150	-108	-23	-19	N/A
9/30/2019	122	-126	-27	-23	N/A
6/30/2019	115	-113	-24	-19	N/A
3/31/2019	115	-87	-18	-14	N/A
12/31/2018	37	-160	-135	-131	N/A
9/30/2018	39	-147	-125	-121	N/A
6/30/2018	29	-151	-127	-123	N/A
3/31/2018	18	-158	-124	-120	N/A
12/31/2017	43	-121	N/A	-94	N/A
9/30/2017	40	-112	N/A	-84	N/A
6/30/2017	41	-116	N/A	-82	N/A
3/31/2017	44	-113	N/A	-73	N/A
12/31/2016	23	-127	N/A	-80	N/A
9/30/2016	25	-117	N/A	-83	N/A
6/30/2016	27	-89	N/A	-78	N/A
3/31/2016	27	-101	N/A	-72	N/A
12/31/2015	25	-88	N/A	-47	N/A
9/30/2015	19	-98	N/A	-38	N/A
6/30/2015	14	-93	N/A	-28	N/A
3/31/2015	10	-61	N/A	-25	N/A
12/31/2014	7	-43	N/A	-38	N/A
9/30/2014	6	-22	N/A	-33	N/A
6/30/2014	5	-22	N/A	-30	N/A
3/31/2014	3	-25	N/A	-26	N/A
12/31/2013	3	-33	N/A	-20	N/A
9/30/2013	4	-33	N/A	-17	N/A
6/30/2013	4	-32	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AGEN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AGENDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: AGENDie Einnahmen des Unternehmens (19.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AGEN in 3 Jahren voraussichtlich hoch sein wird

Agenus Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 27%

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Consensus revenue estimates increase by 30%, EPS downgraded

Price target decreased by 17% to US$6.67

Price target decreased to US$6.33

Price target decreased to US$6.33

Recent updates

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Consensus revenue estimates fall by 27%

New major risk - Financial position

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus’ Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc., Annual General Meeting, Jun 11, 2024

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul

Investor sentiment deteriorated over the past week

Agenus: It's Always Tomorrow

Agenus Initiates Botensilimab Phase 2 Activate Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Agenus Inc. Announces First Patient Dosed in Phase 1 Study of AGEN1571 (Anti-ILT2) in Advanced Solid Tumors

Agenus Inc. to Report Q2, 2022 Results on Aug 09, 2022

Agenus: Successfully Pulled Itself Away From Disaster

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Agenus Inc. Announces Positive Headline Results from A Pre-Specified Efficacy Interim Analysis of the Aresvi 006 Phase III Trial Evaluating Their Investigational RSV Vaccine in Adults Aged 60 Years and Above

Price target decreased to US$7.50

Consensus estimates of losses per share improve by 21%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus Inc., Annual General Meeting, Jun 08, 2022

Insufficient new directors

Agenus: Not Quite Enough

Agenus Inc. Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance